NIH R01 · 2025
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study
Tuberculosis (TB) is a leading global killer among infectious diseases and the leading cause of death among people with HIV. Among the estimated 9 million TB survivors each year, up to half are left with impaired lung function and chronic respiratory symptoms. More than four times as many quality-adjusted life years (QALYs) are lost to post-TB lung disease (PTLD) as are lost to TB mortality. Although there has been growing recognition of PTLD in recent years, there are no known interventions to prevent or treat this devastating outcome. This knowledge gap is due in large part to a fundamental lack of data on mechanisms driving PTLD. Lung damage from TB is often viewed as an inevitable…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.